Target 2035 – update on the quest for a probe for every protein

DOI: 10.1039/D1MD00228G

Authors: Susanne Müller (Goethe University Frankfurt; Structural Genomics Consortium, BMLS, Goethe University Frankfurt) , Suzanne Ackloo (Structural Genomics Consortium, University of Toronto) , Arij Al Chawaf (University of Toronto) , Bissan Al-Lazikani (The Institute of Cancer Research; CRUK ICR/Imperial Convergence Science Centre) , Albert Antolin (The Institute of Cancer Research; The Institute of Cancer Research) , Jonathan B. Baell (Monash University; Nanjing Tech University) , Hartmut Beck (Bayer AG) , Shaunna Beedie (University of Oxford) , Ulrich A. K. Betz (Merck KGaA) , Gustavo Arruda Bezerra (University of Oxford) , Paul E. Brennan (University of Oxford) , David Brown (Institut Recherches de Servier) , Peter J. Brown (Structural Genomics Consortium, University of Toronto) , Alex N. Bullock (University of Oxford) , Adrian J. Carter (Boehringer Ingelheim) , Apirat Chaikuad (Goethe University Frankfurt; Structural Genomics Consortium, BMLS, Goethe University Frankfurt) , Mathilde Chaineau (McGill University) , Alessio Ciulli (University of Dundee) , Ian Collins (The Institute of Cancer Research) , Jan Dreher (Bayer AG) , David Drewry (Structural Genomics Consortium, UNC Eshelman School of Pharmacy; University of North Carolina at Chapel Hill) , Kristina Edfeldt (Karolinska University Hospital and Karolinska Institutet) , Aled M. Edwards (Structural Genomics Consortium, University of Toronto) , Ursula Egner (Nuvisan Innovation Campus Berlin GmbH) , Stephen V. Frye (University of North Carolina at Chapel Hill) , Stephen M. Fuchs (Institute for Protein Innovation) , Matthew D. Hall (National Institutes of Health) , Ingo V. Hartung (Merck Healthcare KGaA) , Alexander Hillisch (Bayer AG) , Stephen H. Hitchcock (Takeda California) , Evert Homan (Karolinska Institutet) , Natarajan Kannan (University of Georgia) , James R. Kiefer (Genentech, Inc) , Stefan Knapp (Goethe University Frankfurt; Structural Genomics Consortium, BMLS, Goethe University Frankfurt) , Milka Kostic (Dana-Farber Cancer Institute) , Stefan Kubicek (CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences) , Andrew S. Leach (European Molecular Biology Laboratory) , Sven Lindemann (Merck Healthcare KGaA) , Brian D. Marsden (University of Oxford) , Hisanori Matsui (Takeda Pharmaceutical Company Limited) , Jordan L. Meier (National Cancer Institute, National Institutes of Health) , Daniel Merk (Goethe University Frankfurt; University of Oxford) , Maurice Michel (Karolinska Institutet) , Maxwell R. Morgan (Structural Genomics Consortium, University of Toronto) , Anke Mueller-Fahrnow (Nuvisan Innovation Campus Berlin GmbH) , Dafydd R. Owen (Pfizer Medicine Design) , Benjamin G. Perry (Drugs for Neglected Diseases initiative) , Saul H. Rosenberg (AbbVie) , Kumar Singh Saikatendu (Takeda California) , Matthieu Schapira (Structural Genomics Consortium, University of Toronto) , Cora Scholten (Bayer AG) , Sujata Sharma (Janssen Research & Development) , Anton Simeonov (National Institutes of Health) , Michael Sundström (Karolinska University Hospital and Karolinska Institutet) , Giulio Superti-Furga (CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences; Medical University of Vienna) , Matthew H. Todd (University College London (UCL)) , Claudia Tredup (University of Georgia) , Masoud Vedadi (Structural Genomics Consortium, University of Toronto) , Frank Von Delft (University of Oxford; Diamond Light Source; University of Johannesburg; Research Complex at Harwell) , Timothy M. Willson (University of North Carolina at Chapel Hill) , Georg E. Winter (CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences) , Paul Workman (CRUK ICR/Imperial Convergence Science Centre; The Institute of Cancer Research) , Cheryl H. Arrowsmith (Structural Genomics Consortium, University of Toronto; Princess Margaret Cancer Centre)
Co-authored by industrial partner: Yes

Type: Journal Paper
Journal: Rsc Medicinal Chemistry , VOL 17

State: Published (Approved)
Published: December 2021

Abstract: Twenty years after the publication of the first draft of the human genome, our knowledge of the human proteome is still fragmented. The challenge of translating the wealth of new knowledge from genomics into new medicines is that proteins, and not genes, are the primary executers of biological function. Therefore, much of how biology works in health and disease must be understood through the lens of protein function. Accordingly, a subset of human proteins has been at the heart of research interests of scientists over the centuries, and we have accumulated varying degrees of knowledge about approximately 65% of the human proteome. Nevertheless, a large proportion of proteins in the human proteome (∼35%) remains uncharacterized, and less than 5% of the human proteome has been successfully targeted for drug discovery. This highlights the profound disconnect between our abilities to obtain genetic information and subsequent development of effective medicines. Target 2035 is an international federation of biomedical scientists from the public and private sectors, which aims to address this gap by developing and applying new technologies to create by year 2035 chemogenomic libraries, chemical probes, and/or biological probes for the entire human proteome.

Subject Areas: Biology and Bio-materials


Technical Areas:

Added On: 07/12/2021 09:30

Documents:
d1md00228g.pdf

Discipline Tags:

Structural biology Life Sciences & Biotech

Technical Tags: